137 related articles for article (PubMed ID: 36929289)
1. Enhancing Oral Performance of Paclitaxel Lipid-Mimic Prodrug via Modulating Type of Fatty Acids.
Miao YF; Ye Q; Zhang MY; Gao L; Wang XY; Zhong WX; Wang ZX; He ZG; Tian CT; Sun J
Adv Healthc Mater; 2023 Jul; 12(19):e2203118. PubMed ID: 36929289
[TBL] [Abstract][Full Text] [Related]
2. Efficient Intestinal Digestion and On Site Tumor-Bioactivation are the Two Important Determinants for Chylomicron-Mediated Lymph-Targeting Triglyceride-Mimetic Docetaxel Oral Prodrugs.
Tian C; Guo J; Wang G; Sun B; Na K; Zhang X; Xu Z; Cheng M; He Z; Sun J
Adv Sci (Weinh); 2019 Dec; 6(24):1901810. PubMed ID: 31871861
[TBL] [Abstract][Full Text] [Related]
3. Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid.
Han S; Quach T; Hu L; Lim SF; Zheng D; Leong NJ; Sharma G; Bonner D; Simpson JS; Trevaskis NL; Porter CJH
Mol Pharm; 2023 May; 20(5):2675-2685. PubMed ID: 36996486
[TBL] [Abstract][Full Text] [Related]
4. Incorporating a Lipophilic Disulfide-Bridged Linoleic Prodrug into a Self-Microemulsifying Drug Delivery System to Facilitate Oral Absorption of Paclitaxel.
Zhang M; Guo C; Miao Y; He Z; Tian C; Sun J
Mol Pharm; 2023 Jan; 20(1):461-472. PubMed ID: 36525349
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
[TBL] [Abstract][Full Text] [Related]
6. The length of disulfide bond-containing linkages impacts the oral absorption and antitumor activity of paclitaxel prodrug-loaded nanoemulsions.
Gao Y; Zuo S; Li L; Liu T; Dong F; Wang X; Zhang X; He Z; Zhai Y; Sun B; Sun J
Nanoscale; 2021 Jun; 13(23):10536-10543. PubMed ID: 34100041
[TBL] [Abstract][Full Text] [Related]
7. Long chain triglyceride-lipid formulation promotes the oral absorption of the lipidic prodrugs through coincident intestinal behaviors.
Tian CT; Guo JJ; Miao YF; Wang HL; Ye Q; Guo CL; Zhang MY; He ZG; Sun J
Eur J Pharm Biopharm; 2022 Jul; 176():122-132. PubMed ID: 35643367
[TBL] [Abstract][Full Text] [Related]
8. Triglyceride-mimetic prodrugs of scutellarin enhance oral bioavailability by promoting intestinal lymphatic transport and avoiding first-pass metabolism.
Wang X; Zhang C; Han N; Luo J; Zhang S; Wang C; Jia Z; Du S
Drug Deliv; 2021 Dec; 28(1):1664-1672. PubMed ID: 34338567
[TBL] [Abstract][Full Text] [Related]
9. Lipidic prodrug approach for improved oral drug delivery and therapy.
Markovic M; Ben-Shabat S; Keinan S; Aponick A; Zimmermann EM; Dahan A
Med Res Rev; 2019 Mar; 39(2):579-607. PubMed ID: 30320896
[TBL] [Abstract][Full Text] [Related]
10. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
11. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Huo M; Zhu Q; Wu Q; Yin T; Wang L; Yin L; Zhou J
J Pharm Sci; 2015 Jun; 104(6):2018-2028. PubMed ID: 25820241
[TBL] [Abstract][Full Text] [Related]
13. Zein-Paclitaxel Prodrug Nanoparticles for Redox-Triggered Drug Delivery and Enhanced Therapeutic Efficiency.
Hou H; Zhang D; Lin J; Zhang Y; Li C; Wang Z; Ren J; Yao M; Wong KH; Wang Y
J Agric Food Chem; 2018 Nov; 66(44):11812-11822. PubMed ID: 30339011
[TBL] [Abstract][Full Text] [Related]
14. Lipophilic Prodrugs of SN38: Synthesis and in Vitro Characterization toward Oral Chemotherapy.
Bala V; Rao S; Li P; Wang S; Prestidge CA
Mol Pharm; 2016 Jan; 13(1):287-94. PubMed ID: 26623947
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs.
Han S; Quach T; Hu L; Lim SF; Gracia G; Trevaskis NL; Simpson JS; Porter CJH
J Pharm Sci; 2021 Jan; 110(1):489-499. PubMed ID: 33069711
[TBL] [Abstract][Full Text] [Related]
16. Constitutive Triglyceride Turnover into the Mesenteric Lymph Is Unable to Support Efficient Lymphatic Transport of a Biomimetic Triglyceride Prodrug.
Han S; Hu L; Quach T; Simpson JS; Trevaskis NL; Porter CJH
J Pharm Sci; 2016 Feb; 105(2):786-796. PubMed ID: 26540595
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Biological Evaluation and Low-Toxic Formulation Development of Glycosylated Paclitaxel Prodrugs.
Mao Y; Zhang Y; Luo Z; Zhan R; Xu H; Chen W; Huang H
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563132
[TBL] [Abstract][Full Text] [Related]
18. Probing the fluorination effect on the self-assembly characteristics,
Wang X; Yang B; Li L; Liu T; Zuo S; Chi D; He Z; Sun B; Sun J
Theranostics; 2021; 11(16):7896-7910. PubMed ID: 34335971
[No Abstract] [Full Text] [Related]
19. Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs.
Han S; Hu L; Gracia ; Quach T; Simpson JS; Edwards GA; Trevaskis NL; Porter CJ
Mol Pharm; 2016 Oct; 13(10):3351-3361. PubMed ID: 27608166
[TBL] [Abstract][Full Text] [Related]
20. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system.
Li M; Thapa P; Rajaputra P; Bio M; Peer CJ; Figg WD; You Y; Woo S
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):521-536. PubMed ID: 28913666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
